Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (7)

The Role of the Small Bowel in Unintentional Weight Loss After Treatment of Upper Gastrointestinal Cancers


The Role of the Small Bowel in Unintentional Weight Loss After Treatment of Upper Gastrointestinal Cancers

Babak Dehestani et al. J Clin Med.


Upper gastrointestinal (GI) cancers are responsible for significant mortality and morbidity worldwide. To date, most of the studies focused on the treatments' efficacy and post-treatment survival rate. As treatments improve, more patients survive long term, and thus the accompanying complications including unintentional weight loss are becoming more important. Unintentional weight loss is defined as >5% of body weight loss within 6-12 months. Malignancies, particularly GI cancers, are diagnosed in approximately 25% of patients who present with unintentional weight loss. Whereas some recent studies discuss pathophysiological mechanisms and new promising therapies of cancer cachexia, there is a lack of studies regarding the underlying mechanism of unintentional weight loss in patients who are tumor free and where cancer cachexia has been excluded. The small bowel is a central hub in metabolic regulation, energy homeostasis, and body weight control throughout the microbiota-gut-brain axis. In this narrative review article, the authors discussed the impacts of upper GI cancers' treatment modalities on the small bowel which may lead to unintentional weight loss and some new promising therapeutic agents to treat unintentional weight loss in long term survivors after upper GI operations with curative intent.

Keywords: cancer; gastrointestinal; small bowl; unintentional; weight loss.

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by 1 article


    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Bitik B., Kalpakci Y., Altan E., Dogan E., Altundag K. Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2009;20:394–395. doi: 10.1093/annonc/mdn741. - DOI - PubMed
    1. Riihimaki M., Hemminki A., Sundquist K., Sundquist J., Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7:52307–52316. doi: 10.18632/oncotarget.10740. - DOI - PMC - PubMed
    1. Voutsadakis I.A., Doumas S., Tsapakidis K., Papagianni M., Papandreou C.N. Bone and brain metastases from ampullary adenocarcinoma. World J. Gastroenterol. 2009;15:2665–2668. doi: 10.3748/wjg.15.2665. - DOI - PMC - PubMed
    1. Wu S.G., Zhang W.W., He Z.Y., Sun J.Y., Chen Y.X., Guo L. Sites of metastasis and overall survival in esophageal cancer: A population-based study. Cancer Manag. Res. 2017;9:781–788. doi: 10.2147/CMAR.S150350. - DOI - PMC - PubMed